Supplemental Table 2: Tumors Site by Myotonic Dystrophy Subtype

Supplemental Table 1: Comparison of demographic, lifestyle, and clinical factors in all DM patients and those with definite/congenital DM diagnosis.

Characteristics / All DM (N=911)
N (%) / Definite/Congenital DM(N=586)
N (%)
DM Type
DM1 / 781 (85.7) / 499 (85.2)
DM2 / 130 (14.3) / 87 (14.8)
Sex
Male / 433 (47.5) / 281 (48.0)
Female / 478 (52.5) / 305 (52.0)
Age at DM Diagnosis
0-25 / 274 (30.1) / 193 (32.9)
26-39 / 341 (37.4) / 191 (32.6)
40+ / 287 (31.5) / 198 (33.8)
Age at Enrollment
0-39 / 352 (38.6) / 286 (48.8)
40-49 / 256 (28.1) / 120 (20.5)
50+ / 303 (33.3) / 181 (30.9)
Race
White, non-Hispanic / 842 (92.4) / 536 (91.5)
Other / 57 (6.3) / 40 (6.8)
Current Tobacco Smoking
Yes / 85 (9.3) / 39 (6.7)
No / 826 (90.7) / 547 (93.3)
Body Mass Index
Underweight (<18.5) / 124 (13.6) / 95 (16.2)
Normal (18.5-24.9) / 382 (41.9) / 256 (43.7)
Overweight (25.0-29.9) / 253 (27.8) / 142 (24.2)
Obese (≥30) / 152 (16.7) / 93 (15.9)
CTG Repeat Size (n=397)
<250 / N/A / 129 (32.5)
250-600 / N/A / 133 (33.5)
>600 / N/A / 135 (34.0)
CCTG Repeat Size (n=54)
<5000 / N/A / 5 (9.3)
5000-12500 / N/A / 15 (27.8)
>12500 / N/A / 34 (63.0)

Abbreviations: DM=myotonicdystrophy, N/A=Not applicable

Supplemental Table 2: Tumors site by myotonic dystrophy subtype

Tumor Site / DM1 (N=79)
N (%) / DM2 (N=16)
N (%)
Skin / 28 (32.9)* / 1 (5.6)
Basal Cell Carcinoma (BCC) / 9 (10.6) / 0 (0)
Melanoma / 6 (7.1) / 0 (0)
Unspecified / 13 (15.3) / 1 (5.6)
Endocrine / 5 (5.9) / 5 (27.8)*
Pituitary / 0 (0) / 1 (5.6)
Pancreas / 0 (0) / 1 (5.6)
Parathyroid / 0 (0) / 1 (5.6)
Thyroid / 5 (5.9) / 2 (11.1)
Breast / 5 (5.9) / 2 (11.1)
Cervix / 4 (4.7) / 0 (0)
Colon / 4 (4.7) / 1 (5.6)
Parotid / 3 (3.5) / 0 (0)
Brain/CNS / 2 (2.4) / 0 (0)
Kidney / 2 (2.4) / 0 (0)
Ovaries / 2 (2.4) / 2 (11.1)
Uterus / 2 (2.4) / 1 (5.6)
Others** / 5 (5.9) / 1(5.6)
Multiple Sites*** / 6 (7.1) / 2 (5.6)
Unspecified / 11 (13.9) / 1 (6.3)

*Statistically significantly different in DM1 vs. DM2 patients (P<0.05) based on Chi-square test

**Others 1 bladder, 1 hematologic, 1 lung, 1 thymus, and 1 uterine in DM1 patients; 1 bladder in DM2

***Patients reporting multiple tumors: DM1 (Uterus and breast; Brain and colon; Cervix and skin (unspecified); Parotid and skin (BCC); Breast and skin (unspecified); and Kidney and skin (unspecified); DM2 (Breast and skin (unspecified); and Breast and thyroid).